Prion Detection via Iron Oxide Bead Extraction and RT-QuIC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting prions in blood are hindered by low circulating levels and inhibitors, making it difficult to identify early pre-clinical infections of neurodegenerative diseases like CJD and CWD, which poses a public health risk due to the potential for transmission through blood donation or surgical interventions.
Innovation Solution
The use of pre-amplification strategies such as sodium phosphotungstate precipitation, PrP antibody-tagging, beads, and lipase treatment, combined with protein misfolding cyclic amplification (PMCA) and real-time quaking-induced conversion (RT-QuIC) assays, specifically with iron oxide bead extraction and RT-QuIC at elevated temperatures, to enhance the detection of prions in buffy coat cells from white-tailed deer and potentially in humans.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used, then the detection process is simple, but the sensitivity is insufficient to detect low circulating levels of prions in blood
Solution Approach 1:
The patent applies pre-amplification strategies including sodium phosphotungstate precipitation, PrP antibody-tagging, beads, and lipase treatment before the main detection assay. These preliminary actions concentrate prions and remove inhibitors from blood samples, enabling subsequent detection of low circulating levels with enhanced sensitivity while managing the complexity through systematic sample preparation steps.
Solution Approach 2:
The patent uses iron oxide beads as an intermediary to facilitate prion detection. The beads bind to prions through magnetic interaction, allowing for concentration and separation of prions from complex blood matrices. This intermediary approach enhances detection sensitivity by isolating target molecules while simplifying the detection process through magnetic separation techniques.
2Reliability
If blood samples are tested for prions, then early pre-clinical infections can be identified, but blood-associated inhibitors interfere with detection
Solution Approach 1:
The patent extracts and removes blood-associated inhibitors through pre-amplification strategies including sodium phosphotungstate precipitation, lipase treatment, and iron oxide bead separation. These extraction steps isolate prions from inhibitory blood components, enabling reliable detection of early pre-clinical infections without interference from blood matrix factors.
Solution Approach 2:
The patent converts the presence of blood components from a harmful factor to a beneficial one by using iron oxide beads that specifically bind to prions in the blood sample. The magnetic beads utilize the blood matrix environment while selectively concentrating prions, transforming the complex blood sample into an advantage for targeted detection rather than a source of interference.
3Measurement precision
If standard detection assays are used, then the procedure is straightforward, but the ability to detect prions in blood components is limited
Solution Approach 1:
The patent implements a multi-step pre-amplification protocol including sodium phosphotungstate precipitation, PrP antibody-tagging, beads, and lipase treatment before the main detection assay. These preliminary actions systematically prepare the sample by concentrating prions and removing inhibitors, enabling detection of low circulating levels while organizing the complexity into manageable sequential steps.
Solution Approach 2:
The patent employs iron oxide beads that serve multiple functions: they bind to prions through magnetic interaction, concentrate the target molecules, facilitate separation from the blood matrix, and enable detection through magnetic separation techniques. This multi-functional approach enhances detection capability while consolidating multiple operations into a single reagent system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the detection of prions in as few as 5×10^5 buffy coat cells, improving the ability to assess the longitudinal course of prion diseases and the role of hematogenous prions in pathogenesis, with enhanced sensitivity and specificity, particularly at higher temperatures, effectively overcoming the limitations of previous detection methods.
Implementation Method 1
The use of pre-amplification strategies such as sodium phosphotungstate precipitation, PrP antibody-tagging, beads, and lipase treatment, combined with protein misfolding cyclic amplification (PMCA) and real-time quaking-induced conversion (RT-QuIC) assays, specifically with iron oxide bead extraction
Implementation Method 2
The use of pre-amplification strategies such as sodium phosphotungstate precipitation, PrP antibody-tagging, beads, and lipase treatment
Implementation Method 3
protein misfolding cyclic amplification (PMCA)
Implementation Method 4
real-time quaking-induced conversion (RT-QuIC) assays, specifically with iron oxide bead extraction and RT-QuIC at elevated temperatures
Implementation Method 5
real-time quaking-induced conversion (RT-QuIC) assays
Data Source
AI summary
A method for the pre-amplification sample processing of a prion or other amyloid converting protein in a sample. A key feature of the assay is its ability to amplify and thus detect small quantities of the abnormally folded ‘seed’ forms of misfolded proteins. The assay also opens up the ability to quantify the amount of “seed” present. The methods facilitate the early detection of diseases associated with misfolded proteins, as well as assessment of therapies against these diseases. The method can detect amyloid seeding activity (prions) in blood samples, including the buffy coat cells harvested from pre-clinical and clinical subjects. These findings further enhance the ability to assess the longitudinal course of prion disease and the role hematogenous prions play in pathogenesis. We demonstrate the ability to detect prions in as few as 5×105 buffy coat cells by lipase-iron oxide bead-RT-QuIC performed at 42° C. (LIQ42) in 79% of CWD-biopsy positive WTD, which increased to 100% when LIQ was performed at 55° C. (LIQ55). RT-QuIC assessment of PMCA (PQ) round 5 product revealed hematogenous prions in 92% of the WTD.